When did enGene Therapeutics (ENGN) last report earnings?

enGene Therapeutics last reported on Dec 22, 2025, covering fiscal Q4 2025.

Did ENGN beat earnings estimates?

No. enGene Therapeutics reported EPS of −$0.73 for Q4 2025 against a −$0.57 estimate — a 28.77% miss.

enGene Therapeutics (ENGN) earnings history

Most recent quarter

Fiscal period: Q4 2025
Period end: Oct 31, 2025
EPS actual: −$0.73
EPS estimate: −$0.57
EPS surprise: −28.77%
Revenue surprise: +0.00%
Revenue: $0.00
Revenue estimate: $0.00
Reported: Dec 22, 2025
SEC filing: View filing

Earnings history

Period	Reported	EPS estimate	EPS actual	Surprise	Revenue	Filing
Q4 2025	Dec 22, 2025	−$0.57	−$0.73	−28.77%	$0.00	SEC
Q2 2025	Jun 12, 2025	−$0.50	−$0.51	−2.55%	$0.00	SEC
Q1 2025	Mar 10, 2025	−$0.37	−$0.48	−30.51%	$0.00	SEC

Quarterly revenue

Q1 2025

$0.00

Q2 2025

$0.00

Q4 2025

$0.00

Frequently asked questions

When did enGene Therapeutics (ENGN) last report earnings?
enGene Therapeutics last reported on Dec 22, 2025, covering fiscal Q4 2025.
Did ENGN beat earnings estimates?
No. enGene Therapeutics reported EPS of −$0.73 for Q4 2025 against a −$0.57 estimate — a 28.77% miss.

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by